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INTRODUCTION

Propofol infusion syndrome (PRIS)
is a rare and fatal syndrome that can
be caused by doses of propofol that
exceed 4mg/kg/hr for more than
48 hours. Concurrent use of cate
cholamines and glucocorticoids
while using propofol has also been
1
linked with PRIS. PRIS can present
with d
 ifferent symptoms including
arrhythmias, metabolic/lactic acidosis,
rhabdomyolysis, renal failure, hypertri
glyceridemia, and cardiac failure.
Symptoms can be associated with
variables such as the rate of infusion
(cardiac failure and metabolic acidosis),
the duration of the infusion (arrhythmias),
or to the c
 umulative amount of propofol
used (rhabdomyolysis and hypertri
2
glyceridemia). These associations
help predict symptoms but are not
strict rules.
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CASE DESCRIPTION

55-year-old female with past medical history of type
1 diabetes presented on day 3 as a transfer from an
outside hospital with worsening hypoxia and day 3 of
ventilator support due to parainfluenza pneumonia.
Physical exam was limited due to sedation with
remarkable findings including bilateral breath sounds
present with end expiratory crackles more prominent
on the right lung base. Abdominal distention was noted
with 1+ pitting edema in the upper and lower extremities.
The dose of propofol on admission was 50 mcg/kg/min
and was slowly increased to a max dose of 80 mcg/kg/
min over the next 3 days. Lab abnormalities on day
6 of hospitalization included creatinine 2.18 mg/dL,
potassium 5.9 mmol/L, bicarbonate 13 mmol/L,
triglyceride 2,192 mg/dL, and creatinine kinase total (CK)
1,483 U/L Based on the lab results, the patient had
developed acute renal failure, severe metabolic acidosis,
hyperkalemia, severe hypertriglyceridemia, and
rhabdomyolysis which increased the suspicion for PRIS.
The patient was promptly started on continuous renal
replacement therapy (CRRT) for the acute renal failure
and started on an insulin drip for the hypertriglyceridemia
which resolved within 24 hours. Her CK normalized
within 3 days. Thankfully the patient was subsequently
taken off the CRRT and recovered fully prior to leaving
the hospital.

DISCUSSION

Due to its favorable pharmacological properties,
propofol is one of the more commonly used
3
agents for sedation in the ICU setting. PRIS is a
rare but potentially fatal syndrome with mortality
rates reaching as high as 66%. Due to its high
mortality rates it is important for physicians to
monitor for early signs of PRIS in order to
decrease the risk of poor outcomes. The current
mainstay of treatment is switching to a different
sedative and providing supportive care to the
patient. In the case presented above the cessation
of propofol and management of its symptoms
and complications led to the patient’s eventual
recovery from PRIS; however, it did increase the
length of stay by a considerable amount.
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